Biomarin Pharmaceutical Inc
BMRN
Company Profile
Business description
BioMarin's focus is on rare-disease therapies. Genzyme markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU. Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the US in 2023.
Contact
770 Lindaro Street
San RafaelCA94901
USAT: +1 415 506-6700
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2024
Employees
3,401
Biomarin Pharmaceutical Inc News & Analysis
stocks
Global healthcare stocks for your watchlist
Subsectors such as biotechnology, pharmaceuticals and diagnostics feature some globally listed names that are trading at discounts.
stocks
5 undervalued global innovative stocks
These names from the Morningstar Exponential Technologies Index are trading at 4- and 5-star levels.
video
4 healthcare stocks attractive on valuation and ESG risk
Morningstar's Karen Andersen explains how environmental, social and governance issues affect Big Pharma and biotech companies.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,567.00 | 12.10 | -0.14% |
| CAC 40 | 7,213.32 | 14.87 | 0.21% |
| DAX 40 | 19,146.17 | 141.39 | 0.74% |
| Dow JONES (US) | 43,949.95 | 541.48 | 1.25% |
| FTSE 100 | 8,149.27 | 64.20 | 0.79% |
| HKSE | 19,601.11 | 103.90 | -0.53% |
| NASDAQ | 18,977.60 | 11.46 | 0.06% |
| Nikkei 225 | 38,026.17 | 326.17 | -0.85% |
| NZX 50 Index | 12,765.24 | 28.18 | 0.22% |
| S&P 500 | 5,951.22 | 34.11 | 0.58% |
| S&P/ASX 200 | 8,323.00 | 3.30 | -0.04% |
| SSE Composite Index | 3,370.40 | 2.41 | 0.07% |